Assessing Ablynx

How Ablynx investors are weighing Novo’s offer for the Belgian biotech

While a group of investors in Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) don’t agree on what is fair value for the Belgian biotech, they do think a $2.8 billion offer from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) undervalues Ablynx’s pipeline and Nanobody platform.

On Jan. 8, both companies disclosed that Novo had made two

Read the full 501 word article

User Sign In